Animalcare Collaborates with 272Bio to Develop Treatment for Equine ‘Sweet Itch’

Animalcare ( (GB:ANCR) ) has provided an announcement.

Animalcare Group plc has announced a collaboration with 272Bio Limited to develop a novel biological treatment for ‘sweet itch,’ a common equine skin condition affecting around 8% of horses globally. This partnership aims to address the significant unmet need in the global equine health market, which is valued at €150m – €200m annually. The collaboration leverages Animalcare’s recent acquisition of the VHH NGF antibody program and strengthens its equine franchise, following the acquisition of Randlab. This initiative is part of Animalcare’s strategy to drive sustainable growth by bringing innovative products to market.

The most recent analyst rating on (GB:ANCR) stock is a Hold with a £284.00 price target. To see the full list of analyst forecasts on Animalcare stock, see the GB:ANCR Stock Forecast page.

Spark’s Take on GB:ANCR Stock

According to Spark, TipRanks’ AI Analyst, GB:ANCR is a Neutral.

Animalcare’s overall stock score reflects strong corporate events and financial stability, offset by bearish technical indicators and high valuation concerns. Strategic expansions and acquisitions bolster future growth potential, but technical analysis suggests caution in the short term.

To see Spark’s full report on GB:ANCR stock, click here.

More about Animalcare

Animalcare Group plc is a UK AIM-listed international veterinary sales and marketing organization operating in seven European countries, as well as Australia, New Zealand, and the UAE. The company exports to approximately 40 countries worldwide and focuses on bringing new and innovative products to market through its development pipeline, partnerships, and acquisitions.

Average Trading Volume: 80,244

Technical Sentiment Signal: Buy

Current Market Cap: £172.5M

For a thorough assessment of ANCR stock, go to TipRanks’ Stock Analysis page.